Tapencarium
Small moleculeexperimental
Clinical trial activity
10 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
10
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2017 (NCT03171415)
Timeline
Indications
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
Loading structure…
SMILES
C[N+](C)(C)CCCCCn1c2ccc(Br)cc2c2cc(Br)ccc21.[Cl-]- Mol. weight
- 488.7 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314928 ↗
Also known as
- rzl-012
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05763160 | Phase 2 | May 29, 2023 | Raziel Therapeutics Ltd. |
| NCT05476679 | Phase 1/Phase 2 (Phase 2) | Sep 25, 2022 | Raziel Therapeutics Ltd. |
| NCT05466448 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2022 | Raziel Therapeutics Ltd. |
| NCT05445557 | Phase 2 | Mar 10, 2022 | Raziel Therapeutics Ltd. |
| NCT04867434 | Phase 2 | Jun 15, 2021 | Raziel Therapeutics Ltd. |
| NCT04229030 | Phase 2 | May 1, 2020 | Raziel Therapeutics Ltd., University of Arizona |
| NCT04086823 | Phase 2 | Nov 28, 2019 | Raziel Therapeutics Ltd. |
| NCT04076891 | Phase 2 | Jun 28, 2018 | Raziel Therapeutics Ltd. |
| NCT03492840 | Phase 2 | May 1, 2018 | Raziel Therapeutics Ltd., University of Arizona |
| NCT03171415 | Phase 2 | Jun 1, 2017 | Raziel Therapeutics Ltd., Spaulding Clinical Research Inc. |
Showing 10 of 10 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Raziel Therapeutics Ltd. | For profit | 10 | 10 | 1 | 2017 |
| University of Arizona | Academic/Hospital | 2 | 0 | 1 | 2018 |
| Spaulding Clinical Research Inc. | For profit | 1 | 0 | 1 | 2017 |
3 organizations
Page 1 / 1